OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation
Nikolaos Karamichalakis, Vasileios Kolovos, Ioannis Paraskevaidis, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 8, pp. 236-236
Open Access | Times Cited: 10
Nikolaos Karamichalakis, Vasileios Kolovos, Ioannis Paraskevaidis, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 8, pp. 236-236
Open Access | Times Cited: 10
Showing 10 citing articles:
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Isabelle C. Van Gelder, Michiel Rienstra, Karina V Bunting, et al.
European Heart Journal (2024)
Open Access | Times Cited: 405
Isabelle C. Van Gelder, Michiel Rienstra, Karina V Bunting, et al.
European Heart Journal (2024)
Open Access | Times Cited: 405
SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
Jiang Li, Yuefeng Yu, Ying Sun, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 26
Jiang Li, Yuefeng Yu, Ying Sun, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 26
The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 9
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 9
The Role of Early Risk Factor Modification and Ablation in Atrial Fibrillation Substrate Remodeling Prevention
Ioanna Koniari, Maria Bozika, Kassiani-Maria Nastouli, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 405-405
Open Access
Ioanna Koniari, Maria Bozika, Kassiani-Maria Nastouli, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 405-405
Open Access
The Influence of Empagliflozin on the Expression of Mitochondrial Regulatory Proteins in Human Myocardium in an Ex Vivo Model of Short-Term Atrial Tachypacing
Paweł Muszyński, Magdalena Cieślińska, Magdalena Dziemidowicz, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1664-1664
Open Access
Paweł Muszyński, Magdalena Cieślińska, Magdalena Dziemidowicz, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1664-1664
Open Access
Effect of SGLT‐2 inhibitors as an add‐on therapy to metformin on P wave indices and atrial electromechanics in type 2 diabetes mellitus patients
Murat Zıyrek, Esra Dönmez, Sevgi Özcan, et al.
Pacing and Clinical Electrophysiology (2023) Vol. 46, Iss. 7, pp. 803-810
Closed Access | Times Cited: 4
Murat Zıyrek, Esra Dönmez, Sevgi Özcan, et al.
Pacing and Clinical Electrophysiology (2023) Vol. 46, Iss. 7, pp. 803-810
Closed Access | Times Cited: 4
Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
Selin Genç, Bahri Evren, Özlem Yiğit, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 11, pp. 1553-1553
Open Access | Times Cited: 1
Selin Genç, Bahri Evren, Özlem Yiğit, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 11, pp. 1553-1553
Open Access | Times Cited: 1
Therapeutic effects of sodium–glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction: From outcome improvement to potentially favourable influences on atrial fibrillation burden, atrial fibrillation progression and atrial cardiomyopathy
Giuseppe Boriani, Davide Antonio Mei, Jacopo Francesco Imberti
European Journal of Heart Failure (2023) Vol. 25, Iss. 7, pp. 978-980
Closed Access | Times Cited: 3
Giuseppe Boriani, Davide Antonio Mei, Jacopo Francesco Imberti
European Journal of Heart Failure (2023) Vol. 25, Iss. 7, pp. 978-980
Closed Access | Times Cited: 3
New Perspectives on Risk Stratification and Treatment in Patients with Atrial Fibrillation: An Analysis of Recent Contributions on the Journal of Cardiovascular Disease and Development
Giuseppe Boriani, Niccolò Bonini, Jacopo Francesco Imberti, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 2, pp. 61-61
Open Access
Giuseppe Boriani, Niccolò Bonini, Jacopo Francesco Imberti, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 2, pp. 61-61
Open Access
Fibrillation auriculaire : la grande oubliée des complications des diabètes. Un espoir nommé inhibiteurs des SGLT-2
Serge Halimi
Médecine des Maladies Métaboliques (2022)
Closed Access
Serge Halimi
Médecine des Maladies Métaboliques (2022)
Closed Access
